Differential effects of lipid-lowering agents on human cholinesterases

Sultan Darvesh; Earl Martin; Ryan Walsh; Kenneth Rockwood

doi:10.1016/j.clinbiochem.2003.09.004

Differential effects of lipid-lowering agents on human cholinesterases

Sultan Darvesh, Earl Martin, Ryan Walsh, Kenneth Rockwood

Résultat de recherche: Article › examen par les pairs

38 Citations (Scopus)

Résumé

Objectives: Epidemiologic reports indicate that lipid-lowering agents (LLAs) protect against dementia. We hypothesized that LLAs might affect cholinergic systems. The effects of LLAs on the activity of cholinesterases were examined. Design and methods: Odds ratios and relative risks were calculated from clinical studies of LLAs and dementia and compared with their impacts on human cholinesterases. Representative LLAs were examined for their effects on the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) using Ellman's assay. Results: Epidemiological studies, but not clinical trials, showed lower odds of dementia in patients taking "statins". Comparison of LLAs indicated that "statins" most consistently produced apparent protection. Individual "statins" showed differential cholinesterase inhibition. Lovastatin and simvastatin significantly inhibited butyrylcholinesterase, while mevastatin, pravastatin and the "non-statins" did not. None of the LLAs inhibited acetylcholinesterase. Conclusions: Some "statins" inhibit butyrylcholinesterase. This inhibition suggests a possible means whereby "statins" could protect against dementia.

Langue d'origine	English
Pages (de-à)	42-49
Nombre de pages	8
Journal	Clinical Biochemistry
Volume	37
Numéro de publication	1
DOI	https://doi.org/10.1016/j.clinbiochem.2003.09.004
Statut de publication	Published - janv. 2004

Note bibliographique

Funding Information:
Dr. Darvesh is a Clinical Research Scholar of the Faculty of Medicine, Dalhousie University. Dr. Rockwood is supported by an Investigator Award from the Canadian Institutes of Health Research and by the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research, which provided funding for this study. Additional funds that contributed to the support of this work came from the Canadian Institutes of Health Research, Queen Elizabeth II Health Science Centre Research Fund, Heart and Stroke Foundation of New Brunswick, and the Committee on Research and Publications of Mount Saint Vincent University.

ASJC Scopus Subject Areas

Clinical Biochemistry

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

Accès au document

10.1016/j.clinbiochem.2003.09.004

Autres fichiers et liens

Citer

@article{180a0160fdbd4c779068bcb39dc358a2,

title = "Differential effects of lipid-lowering agents on human cholinesterases",

abstract = "Objectives: Epidemiologic reports indicate that lipid-lowering agents (LLAs) protect against dementia. We hypothesized that LLAs might affect cholinergic systems. The effects of LLAs on the activity of cholinesterases were examined. Design and methods: Odds ratios and relative risks were calculated from clinical studies of LLAs and dementia and compared with their impacts on human cholinesterases. Representative LLAs were examined for their effects on the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) using Ellman's assay. Results: Epidemiological studies, but not clinical trials, showed lower odds of dementia in patients taking {"}statins{"}. Comparison of LLAs indicated that {"}statins{"} most consistently produced apparent protection. Individual {"}statins{"} showed differential cholinesterase inhibition. Lovastatin and simvastatin significantly inhibited butyrylcholinesterase, while mevastatin, pravastatin and the {"}non-statins{"} did not. None of the LLAs inhibited acetylcholinesterase. Conclusions: Some {"}statins{"} inhibit butyrylcholinesterase. This inhibition suggests a possible means whereby {"}statins{"} could protect against dementia.",

author = "Sultan Darvesh and Earl Martin and Ryan Walsh and Kenneth Rockwood",

note = "Funding Information: Dr. Darvesh is a Clinical Research Scholar of the Faculty of Medicine, Dalhousie University. Dr. Rockwood is supported by an Investigator Award from the Canadian Institutes of Health Research and by the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research, which provided funding for this study. Additional funds that contributed to the support of this work came from the Canadian Institutes of Health Research, Queen Elizabeth II Health Science Centre Research Fund, Heart and Stroke Foundation of New Brunswick, and the Committee on Research and Publications of Mount Saint Vincent University.",

year = "2004",

month = jan,

doi = "10.1016/j.clinbiochem.2003.09.004",

language = "English",

volume = "37",

pages = "42--49",

journal = "Clinical Biochemistry",

issn = "0009-9120",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Differential effects of lipid-lowering agents on human cholinesterases

AU - Darvesh, Sultan

AU - Martin, Earl

AU - Walsh, Ryan

AU - Rockwood, Kenneth

N1 - Funding Information: Dr. Darvesh is a Clinical Research Scholar of the Faculty of Medicine, Dalhousie University. Dr. Rockwood is supported by an Investigator Award from the Canadian Institutes of Health Research and by the Dalhousie Medical Research Foundation as the Kathryn Allen Weldon Professor of Alzheimer Research, which provided funding for this study. Additional funds that contributed to the support of this work came from the Canadian Institutes of Health Research, Queen Elizabeth II Health Science Centre Research Fund, Heart and Stroke Foundation of New Brunswick, and the Committee on Research and Publications of Mount Saint Vincent University.

PY - 2004/1

Y1 - 2004/1

N2 - Objectives: Epidemiologic reports indicate that lipid-lowering agents (LLAs) protect against dementia. We hypothesized that LLAs might affect cholinergic systems. The effects of LLAs on the activity of cholinesterases were examined. Design and methods: Odds ratios and relative risks were calculated from clinical studies of LLAs and dementia and compared with their impacts on human cholinesterases. Representative LLAs were examined for their effects on the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) using Ellman's assay. Results: Epidemiological studies, but not clinical trials, showed lower odds of dementia in patients taking "statins". Comparison of LLAs indicated that "statins" most consistently produced apparent protection. Individual "statins" showed differential cholinesterase inhibition. Lovastatin and simvastatin significantly inhibited butyrylcholinesterase, while mevastatin, pravastatin and the "non-statins" did not. None of the LLAs inhibited acetylcholinesterase. Conclusions: Some "statins" inhibit butyrylcholinesterase. This inhibition suggests a possible means whereby "statins" could protect against dementia.

AB - Objectives: Epidemiologic reports indicate that lipid-lowering agents (LLAs) protect against dementia. We hypothesized that LLAs might affect cholinergic systems. The effects of LLAs on the activity of cholinesterases were examined. Design and methods: Odds ratios and relative risks were calculated from clinical studies of LLAs and dementia and compared with their impacts on human cholinesterases. Representative LLAs were examined for their effects on the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) using Ellman's assay. Results: Epidemiological studies, but not clinical trials, showed lower odds of dementia in patients taking "statins". Comparison of LLAs indicated that "statins" most consistently produced apparent protection. Individual "statins" showed differential cholinesterase inhibition. Lovastatin and simvastatin significantly inhibited butyrylcholinesterase, while mevastatin, pravastatin and the "non-statins" did not. None of the LLAs inhibited acetylcholinesterase. Conclusions: Some "statins" inhibit butyrylcholinesterase. This inhibition suggests a possible means whereby "statins" could protect against dementia.

UR - http://www.scopus.com/inward/record.url?scp=0347481473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347481473&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2003.09.004

DO - 10.1016/j.clinbiochem.2003.09.004

M3 - Article

C2 - 14675561

AN - SCOPUS:0347481473

SN - 0009-9120

VL - 37

SP - 42

EP - 49

JO - Clinical Biochemistry

JF - Clinical Biochemistry

IS - 1

ER -

Differential effects of lipid-lowering agents on human cholinesterases

Résumé

Note bibliographique

ASJC Scopus Subject Areas

PubMed: MeSH publication types

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer